Novavax (NVAX): Un Nuevo Comienzo

Novavax GAAP EPS of -$6.53, revenue of $185.93M misses by $834.07M, lowers 2022 revenue forecast

• Novavax (NASDAQ:NVAX) Press Release: Q2 GAAP EPS of -$6.53
• Revenue of $185.93M (-37.6% Y/Y)  misses by $834.07M.
• Revising full year 2022 total revenue guidance to $2 to $2.3 billion from prior outlook of $4B-$5B ($4.27B consensus). Total revenue reflects all sources, including product sales of Nuvaxovid by Novavax, grants revenue, royalties and other revenue.
• Second quarter of 2022 total revenue includes $78 million of revenue comprised of $55 million of product sales from NVX-CoV2373 based on three million doses sold by Novavax and $23 million of royalties, milestone, and adjuvant sales to our license partners.
• Nuvaxovid and Covovax authorized for adults in 43 countries, with booster authorizations in Japan, Australia and New Zealand as well as, adolescent authorizations in the EU, Australia, India, Japan, and Thailand
• Over 73 million doses delivered globally to date
• Expect to file for authorization of Omicron-containing vaccine with U.S. FDA in the fourth quarter of 2022

https://seekingalpha.com/news/3869164-novavax-gaap-eps-of-653-revenue-of-18593m-misses-by-83407m-lowers-2022-revenue-forecast?mailingid=28659571&messageid=2900&serial=28659571.7210&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha&utm_term=28659571.7210